The combination astemizole–gefitinib as a potential therapy for human lung cancer

References

• FerlayJSoerjomataramIErvikMCancer Incidence and Mortality Worldwide: IARC CancerBase No 11Lyon, FranceInternational Agency for Research on Cancer2013 GLOBOCAN 2012 v1
   Google Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• EspositoLContiDAilavajhalaRKhalilNGiordanoALung cancer: are we up to the challenge?Curr Genomics201011751351821532835
   PubMedGoogle Scholar
• de GrootPMundenRFLung cancer epidemiology, risk factors, and preventionRadiol Clin North Am201250586387622974775
   PubMed Web of Science ®Google Scholar
• ChanBAHughesBGTargeted therapy for non-small cell lung cancer: current standards and the promise of the futureTrans Lung Cancer Res20154136
   PubMed Web of Science ®Google Scholar
• LiuXWangPZhangCMaZEpidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancerOncotarget2017830502095022028430586
   PubMedGoogle Scholar
• ZhuQZhangSDingXHeBZhangHDriver genes in non-small cell lung cancer: characteristics, detection methods, and targeted therapiesOncotarget2017834576805769228915704
   PubMedGoogle Scholar
• JackmanDMYeapBYSequistLVExon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinibClin Cancer Res200612133908391416818686
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• ZhangHThree generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerDrug Des Devel Ther2016103867
   PubMed Web of Science ®Google Scholar
• KrisMGNataleRBHerbstRSEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA2003290162149215814570950
   PubMed Web of Science ®Google Scholar
• Hopper-BorgeEANastoRERatushnyVWeinerLMGolemisEAAstsaturovIMechanisms of tumor resistance to EGFR-targeted therapiesExpert Opin Ther Targets200913333936219236156
   PubMed Web of Science ®Google Scholar
• Özvegy-LaczkaCCserepesJElkindNBSarkadiBTyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transportersDrug Resist Updat200581152615939339
   PubMedGoogle Scholar
• SharomFJABC multidrug transporters: structure, function and role in chemoresistancePharmacogenomics20089110512718154452
   PubMed Web of Science ®Google Scholar
• LeeHKangSKimWDrug repositioning for cancer therapy based on large-scale drug-induced transcriptional signaturesPLoS One2016113e015046026954019
   PubMedGoogle Scholar
• EllegaardA-MDehlendorffCVindACRepurposing cationic amphiphilic antihistamines for cancer treatmentEBioMedicine2016913013927333030
   PubMed Web of Science ®Google Scholar
• AshburnTTThorKBDrug repositioning: identifying and developing new uses for existing drugsNat Rev Drug Discov20043867368315286734
   PubMed Web of Science ®Google Scholar
• ChengFLiuCJiangJPrediction of drug-target interactions and drug repositioning via network-based inferencePLoS Comput Biol201285e100250322589709
   PubMed Web of Science ®Google Scholar
• ParsonsMEGanellinCRHistamine and its receptorsBr J Pharmacol2006147S1S127S13516402096
   PubMedGoogle Scholar
• García-QuirozJCamachoJAstemizole: an old anti-histamine as a new promising anti-cancer drugAnticancer Agents Med Chem201111330731421443504
   PubMed Web of Science ®Google Scholar
• ReynoldsJAkhterJMorrisDIn vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell linesMelanoma Res199662951008791266
   PubMedGoogle Scholar
• García-FerreiroREKerschensteinerDMajorFMonjeFStühmerWPardoLAMechanism of block of hEag1 K+ channels by imipramine and astemizoleJ Gen Physiol2004124430131715365094
   PubMedGoogle Scholar
• DiazLCeja-OchoaIRestrepo-AnguloIEstrogens and human papilloma virus oncogenes regulate human ether-a-go-go-1 potassium channel expressionCancer Res20096983300330719351862
   PubMed Web of Science ®Google Scholar
• DownieBRSánchezAKnötgenHEag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumorsJ Biol Chem200828352362343624018927085
   PubMed Web of Science ®Google Scholar
• PardoLAStühmerWEag1: an emerging oncological targetCancer Res20086861611161318339837
   PubMed Web of Science ®Google Scholar
• WulffHCastleNAPardoLAVoltage-gated potassium channels as therapeutic targetsNat Rev Drug Discov2009812982100119949402
   PubMed Web of Science ®Google Scholar
• AvilaEGarcia-BecerraRRodríguez-RasgadoJACalcitriol down-regulates human ether a go-go 1 potassium channel expression in cervical cancer cellsAnticancer Res20103072667267220682996
   PubMedGoogle Scholar
• de Guadalupe Chávez-LópezMPérez-CarreónJIZuñiga-GarcíaVAstemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCCTumor Biol201536861496158
   PubMedGoogle Scholar
• PardoLAdel CaminoDSanchezAOncogenic potential of EAG K(+) channelsEMBO J199918205540554710523298
   PubMed Web of Science ®Google Scholar
• Rodriguez-RasgadoJAAcuna-MaciasICamachoJEag1 channels as potential cancer biomarkersSensors20121255986599522778627
   PubMedGoogle Scholar
• OcchiodoroTBernheimLLiuJ-HCloning of a human ether-à-go-go potassium channel expressed in myoblasts at the onset of fusionFEBS Lett19984341–21771829738473
   PubMedGoogle Scholar
• HemmerleinBWeselohRMde QueirozFMOverexpression of Eag1 potassium channels in clinical tumoursMol Cancer2006514117022810
   PubMedGoogle Scholar
• FariasLMBOcañaDBDíazLEther a go-go potassium channels as human cervical cancer markersCancer Res200464196996700115466192
   PubMed Web of Science ®Google Scholar
• OusingsawatJSpitznerMPuntheeranurakSExpression of voltage-gated potassium channels in human and mouse colonic carcinomaClin Cancer Res200713382483117289873
   PubMed Web of Science ®Google Scholar
• OrtizCSMontante-MontesDSaqui-SalcesMEag1 potassium channels as markers of cervical dysplasiaOncol Rep20112661377138321887469
   PubMed Web of Science ®Google Scholar
• García-QuirozJGarcía-BecerraRBarreraDAstemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapyPLoS One201279e4506322984610
   PubMed Web of Science ®Google Scholar
• IshikawaMFujitaRTakayanagiMTakayanagiYSasakiKReversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizoleBiol Pharm Bull200023111211510706423
   PubMedGoogle Scholar
• García-BecerraRDíazLCamachoJCalcitriol inhibits Ether-a go-go potassium channel expression and cell proliferation in human breast cancer cellsExp Cell Res2010316343344219932096
   PubMedGoogle Scholar
• KongXChenLJiaoLAstemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2J Med Chem201457229512952125369470
   PubMed Web of Science ®Google Scholar
• XuRShenHGuoRSunJGaoWShuYCombine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinibBiomed Pharmacother201266538438922560634
   PubMedGoogle Scholar
• StabileLPLykerJSGubishCTZhangWGrandisJRSiegfriedJMCombined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effectsCancer Res20056541459147015735034
   PubMed Web of Science ®Google Scholar
• de Guadalupe Chávez-LópezMHernández-GallegosEVázquez-SánchezAYGariglioPCamachoJAntiproliferative and proapoptotic effects of astemizole on cervical cancer cellsInt J Gynecol Cancer201424582482824819656
   PubMedGoogle Scholar
• YadavMSinghAKKumarHEpidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptorsBiochim Biophys Acta20161860102178219027180173
   PubMedGoogle Scholar
• NolenTMSedative effects of antihistamines: safety, performance, learning, and quality of lifeClin Ther1997193955
   PubMed Web of Science ®Google Scholar
• KingswoodJCRoutledgePALazarisJHA report of overdose with astemizoleHum Toxicol1986543443081429
   PubMedGoogle Scholar
• BishopROGaudryPLProlongated Q-T interval following astemizole overdoseArch Emerg Med1989663652565725
   PubMedGoogle Scholar
• CraftTMTorsade de pointes after astemizole overdoseBr Med J1986292660
   PubMed Web of Science ®Google Scholar